High-Quality Ibutamoren Mesylate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex
High-Quality Ibutamoren Mesylate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex Detail:
Product Detail
| Name | Eptifibatide |
| CAS number | 188627-80-7 |
| Molecular formula | C35H49N11O9S2 |
| Molecular weight | 831.96 |
| EINECS Number | 641-366-7 |
| Density | 1.60±0.1 g/cm3(Predicted) |
| Storage conditions | Sealed in dry, store in freezer, under -15°C |
Synonyms
Eptifibatideacetatesalt;Eptifibatide,MPA-HAR-Gly-Asp-Trp-Pro-Cys-NH2,MPAHARGDWPC-NH2,>99%;MAP-LYS-GLY-ASP-TRP-PRO-CYS-NH2;INTEGRELIN;Eptifibatide;N6-(Aminoiminomethyl)-N2-(3-mercapto-1-oxopropyl-L-lysylglycyl-L-a-aspartyl-L-tryptophyl-L-prolyl-L-cysteinamide;MPA-HAR-GLY-ASP-TRP-PRO-CYS-NH2(DISULFIDEBRIDGE,MPA1-CYS6).
Platelet Glycoprotein Antagonist
Etifibatide (integrilin) is a novel polypeptide platelet glycoprotein IIb/IIIa receptor antagonist, which inhibits platelet aggregation and thrombosis by inhibiting the last common pathway of platelet aggregation. Compared with the monoclonal antibody abciximab, eptifibatide has a stronger, more directional and specific binding to GPIIb/IIIa due to the existence of a single conservative amino acid substitution—lysine to replace arginine. Therefore, it should have a good therapeutic effect in the interventional treatment of acute coronary syndrome. Platelet glycoprotein IIb/IIIa receptor antagonist drugs have been developed a lot, and currently there are 3 kinds of preparations that can be used in clinical internationally, abciximab, eptifibatide and tirofiban. ). There is little experience in the use of platelet glycoprotein GPIIb/IIIa receptor antagonists in China, and the available drugs are also very limited. Only one drug, tirofiban hydrochloride, is on the market. Therefore, a new platelet glycoprotein IIb was developed. /IIIa receptor antagonists are imperative. Domestic eptifibatide is an imitation product produced by Chengdu Sino Biological Products Co., Ltd.
Classification
Classification of Antiplatelet Aggregation Drugs
Antiplatelet aggregation drugs can be roughly divided into three categories: 1. Cyclooxygenase-1 (COX-1) inhibitors, such as aspirin. 2. Inhibit platelet aggregation induced by adenosine diphosphate (ADP), such as clopidogrel, prasugrel, cangrelor, ticagrelor, etc. 3. Platelet glycoprotein Ⅱb/Ⅲa receptor antagonists, such as abciximab, eptifibatide, tirofiban, etc. In addition, there are prostaglandin EP3 receptor inhibitors, newly synthesized chemical components and effective extracts from traditional Chinese medicine.
Product detail pictures:
Related Product Guide:
"Control the standard by the details, show the power by quality". Our business has strived to establish a highly efficient and stable team staff and explored an effective good quality regulate course of action for High-Quality Ibutamoren Mesylate - Eptifibatide for Treatment of Acute Coronary Syndrome 188627-80-7 – Gentolex , The product will supply to all over the world, such as: British, Czech republic, Porto, If any item be of interest to you, you should let us know. We will try our best to satisfy your requirements with high quality goods, the best prices and prompt delivery. You should feel free to contact us at any time. We will reply you when we receive your inquiries. Make sure you note that samples are available before we start our business.
By Matthew Tobias from Ethiopia - 2018.12.10 19:03
This company can be well to meet our needs on product quantity and delivery time, so we always choose them when we have procurement requirements.
By Alex from Serbia - 2018.09.08 17:09
